NCT02795273

Efficacy and Safety of Grass-SPIRE Registration Study

A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis

• Status: Withdrawn
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Circassia Limited · Industry
• Sex: All
• Age: 12 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication during the grass pollen season

Conditions

• Rhinitis
• Conjunctivitis

Interventions

Type	Name	Description
DRUG	Grass-SPIRE
DRUG	Placebo

Timeline

• Start date: 2016-05-01
• Primary completion: 2018-10-01
• First posted: 2016-06-10
• Last updated: 2016-06-23

Locations

2 sites across 1 country: United States